Financial statements Notes to the financial statements 27 Trade and other payables 2013 2012 m m Trade payables 2,739 2,666 Wages and salaries 1,049 915 Social security 109 112 Other payables 906 881 Deferred income 167 162 Customer return and rebate accruals 1,599 1,640 Other accruals 1,748 1,678 8,317 8,054 At 31 December 2013, Other payables include 620 million in respect of the maximum potential amount payable to non-controlling shareholders in GSK Pharmaceuticals Ltd, the Groups pharmaceuticals subsidiary in India, under a voluntary open offer to purchase additional shares announced in December 2013.
The purchase is expected to complete in the first half of 2014.
At 31 December 2012, Other payables include 585 million in respect of the maximum potential amount payable to non-controlling shareholders in GSK Consumer Healthcare Ltd, the Groups consumer healthcare subsidiary in India see Note 39.
Customer return and rebate accruals are provided for by the Group at the point of sale in respect of the estimated rebates, discounts or allowances payable to customers, including 1,188 million 2012 1,210 million in respect of US Pharmaceuticals and Vaccines.
Accruals are made at the time of sale but the actual amounts paid are based on claims made some time after the initial recognition of the sale.
As the amounts are estimated they may not fully reflect the final outcome and are subject to change dependent upon, amongst other things, the types of buying group and product sales mix.
The level of accrual is reviewed and adjusted quarterly in the light of historical experience of actual rebates, discounts or allowances given and returns made and any changes in arrangements.
Future events could cause the assumptions on which the accruals are based to change, which could affect the future results of the Group.
Trade and other payables include 9 million 2012 19 million due to associates and joint ventures.
28 Pensions and other post-employment benefits 2012 2011 2013 restated restated Pension and other post-employment costs m m m UK pension schemes 139 230 112 US pension schemes 95 92 89 Other overseas pensions schemes 111 129 129 Unfunded post-retirement healthcare schemes 175 104 84 170 95 414 Analysed as: Funded defined benefit hybrid pension schemes 283 67 258 Unfunded defined benefit pension schemes 30 14 26 Unfunded post-retirement healthcare schemes 175 104 84 Defined benefit schemes 138 51 368 Defined contribution pension schemes 32 44 46 170 95 414 The net reduction in the post-retirement healthcare schemes cost in 2013 arises from the restructuring of US post-retirement medical obligations.
The reduction in the UK pension scheme cost in 2012 relates to the one-off adjustments arising from the capping of future pensionable salary increases and a change in the basis of future discretionary pension increased from RPI to CPI in certain legacy plans.
For further details see page 165.
The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: 2012 2011 2013 restated restated m m m Cost of sales 104 2 118 Selling, general and administration 27 114 196 Research and development 7 61 54 138 51 368 GSK entities operate pension arrangements which cover the Groups material obligations to provide pensions to retired employees.
These arrangements have been developed in accordance with local practices in the countries concerned.
Pension benefits can be provided by state schemes: by defined contribution schemes, whereby retirement benefits are determined by the value of funds arising from contributions paid in respect of each employee: or by defined benefit schemes, whereby retirement benefits are based on employee pensionable remuneration and length of service.
Some hybrid defined benefit schemes also include defined contribution sections.
